Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evocalcet vs Cinacalcet in Secondary Hyperparathyroidism on Hemodialysis
NCT03822507Phase 3Completed
- Sponsor
- Kyowa Kirin
- Start
- Apr 2019
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial of ASP7991 in secondary hyperparathyroidism (SHPT) (2 arms), sponsored by Kyowa Kirin. Primary endpoint: Mean percent change in intact parathyroid hormone (PTH) level from baseline. Started Apr 2019; status: completed.
02
Drugs
ASP7991
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT03822507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03822507.